Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Kohl's Corporation (KSS) vs Revvity Inc (RVTY) Price & Performance

Kohl's CorporationTrade
Revvity IncTrade

Price performance (Past 24H)

Key statistics

Kohl's Corporation vs Revvity Inc — how do they compare? Kohl's Corporation trades at $20.35 (market cap $2.28B), while Revvity Inc trades at $154.18 (market cap $16.98B). The key difference: Revvity Inc is far larger — about 7.4× Kohl's Corporation's market cap, and Kohl's Corporation pays the higher dividend (2.49%). Which is the better fit depends on your goals — on Pluang, investors hold Kohl's Corporation for 48 Days and Revvity Inc for 12 Days on average.

KSSRVTY
Market Cap
$2.28B$16.98B
Volume
4,960,2801,456,900
Sector
Consumer CyclicalHealth
52-Week High
$24.71$157.36
52-Week Low
$11.72$82.26
Typical Hold Time
48 Days12 Days
Enterprise Value
$7.88B$19.30B
Dividend Yield
2.49%0.18%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Kohl's Corporation

Kohl's (KSS) trades at $20.35, up 1.14% with a bullish technical outlook despite recent earnings beats. The stock shows attractive valuation metrics with P/E of 8.63 and P/S of 0.15, though revenue has declined from $19.4B in 2022 to $16.2B in 2025. Recent Q2 2026 earnings beat expectations with $1.28 EPS versus $0.58 expected, and the company raised full-year guidance amid merchandising improvements.

KSS presents a value opportunity with strong fundamentals but faces headwinds from 18 consecutive quarters of declining sales. Analyst consensus is mixed with 30% buy ratings and a $15.50 price target below current levels. The turnaround story depends on holiday execution and sales stabilization to sustain recent gains beyond tariff-related benefits.

Revvity Inc

Revvity (RVTY) trades at $154.18, up 0.38% today and near its 52-week high of $158.28. The stock shows a bullish technical trend with strong moving averages and has beaten earnings estimates for the last three quarters. Recent developments include the launch of a new diabetes screening kit in Europe and the acquisition of Human Cell Design to expand its metabolic disease research tools. Revenue remains stable around $2.9 billion, though net income margin is modest at 8.16%.

The outlook is positive with analyst consensus leaning buy (51.72%) and a price target of $132.13, though the current price exceeds it. Key opportunities include diagnostic growth and AI-driven demand, while risks involve premium valuation (P/E 73.15), margin pressures, and exposure to China market volatility. Earnings on November 3, 2026, will be critical for near-term direction.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

KSS

No sentiment data available yet.

RVTY
0% Buy100% Sell
Avg holding period · 12 Days

Top news

Latest headlines on both assets

About Kohl's Corporation

Kohl's operates 1,165 department stores in 49 states that sell moderately priced private-label and national brand clothing, shoes, accessories, cosmetics, and home furnishings. Most of these stores are in strip centers. Kohl's also operates a large digital sales business. Women's apparel is Kohl's largest category, having generated 27% of its 2021 sales. The retailer, headquartered in Menomonee Falls, Wisconsin, opened its first department store in 1962.

Read more on KSS →

About Revvity Inc

Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.

Read more on RVTY →